## Daniela S Krause

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8905812/publications.pdf

Version: 2024-02-01

54 papers

4,268 citations

346980 22 h-index 242451 47 g-index

55 all docs 55 docs citations

55 times ranked 7187 citing authors

#	Article	IF	CITATIONS
1	The differential role of the lipid raft-associated protein flotillin 2 for progression of myeloid leukemia. Blood Advances, 2022, 6, 3611-3624.	2.5	6
2	Chronic Myeloid Leukemia: A Model Disease of the Past, Present and Future. Cells, 2021, 10, 117.	1.8	75
3	Germline variants drive myelodysplastic syndrome in young adults. Leukemia, 2021, 35, 2439-2444.	3.3	43
4	Recent advances in understanding chronic myeloid leukemia: where do we stand?. Faculty Reviews, 2021, 10, 35.	1.7	8
5	Evading eviction: leukemic stem cell squatters. Blood, 2021, 138, 1007-1008.	0.6	2
6	The age of the bone marrow microenvironment influences B-cell acute lymphoblastic leukemia progression via CXCR5-CXCL13. Blood, 2021, 138, 1870-1884.	0.6	20
7	The mRNA m6A reader YTHDF2 suppresses proinflammatory pathways and sustains hematopoietic stem cell function. Journal of Experimental Medicine, 2021, 218, .	4.2	90
8	The vascular bone marrow niche influences outcome in chronic myeloid leukemia <i>via</i> the E-selectin - SCL/TAL1 - CD44 axis. Haematologica, 2020, 105, 136-147.	1.7	44
9	"Caught in the net― the extracellular matrix of the bone marrow in normal hematopoiesis and leukemia. Experimental Hematology, 2020, 89, 13-25.	0.2	22
10	The Fox(o) and the HDAC. Blood, 2020, 135, 1416-1417.		0
		0.6	0
11	Bone marrow niches in haematological malignancies. Nature Reviews Cancer, 2020, 20, 285-298.	12.8	270
11			
	Bone marrow niches in haematological malignancies. Nature Reviews Cancer, 2020, 20, 285-298.  Bone marrow niche-derived extracellular matrix-degrading enzymes influence the progression of	12.8	270
12	Bone marrow niches in haematological malignancies. Nature Reviews Cancer, 2020, 20, 285-298.  Bone marrow niche-derived extracellular matrix-degrading enzymes influence the progression of B-cell acute lymphoblastic leukemia. Leukemia, 2020, 34, 1540-1552.  Specific, targetable interactions with the microenvironment influence imatinib-resistant chronic	12.8 3.3	270
12	Bone marrow niches in haematological malignancies. Nature Reviews Cancer, 2020, 20, 285-298.  Bone marrow niche-derived extracellular matrix-degrading enzymes influence the progression of B-cell acute lymphoblastic leukemia. Leukemia, 2020, 34, 1540-1552.  Specific, targetable interactions with the microenvironment influence imatinib-resistant chronic myeloid leukemia. Leukemia, 2020, 34, 2087-2101.  Updates on the hematologic tumor microenvironment and its therapeutic targeting. Haematologica,	12.8 3.3 3.3	270 46 22
12 13 14	Bone marrow niches in haematological malignancies. Nature Reviews Cancer, 2020, 20, 285-298.  Bone marrow niche-derived extracellular matrix-degrading enzymes influence the progression of B-cell acute lymphoblastic leukemia. Leukemia, 2020, 34, 1540-1552.  Specific, targetable interactions with the microenvironment influence imatinib-resistant chronic myeloid leukemia. Leukemia, 2020, 34, 2087-2101.  Updates on the hematologic tumor microenvironment and its therapeutic targeting. Haematologica, 2019, 104, 1928-1934.  Vitamin K antagonism impairs the bone marrow microenvironment and hematopoiesis. Blood, 2019, 134,	12.8 3.3 3.3	270 46 22 42
12 13 14	Bone marrow niches in haematological malignancies. Nature Reviews Cancer, 2020, 20, 285-298.  Bone marrow niche-derived extracellular matrix-degrading enzymes influence the progression of B-cell acute lymphoblastic leukemia. Leukemia, 2020, 34, 1540-1552.  Specific, targetable interactions with the microenvironment influence imatinib-resistant chronic myeloid leukemia. Leukemia, 2020, 34, 2087-2101.  Updates on the hematologic tumor microenvironment and its therapeutic targeting. Haematologica, 2019, 104, 1928-1934.  Vitamin K antagonism impairs the bone marrow microenvironment and hematopoiesis. Blood, 2019, 134, 227-238.	12.8 3.3 3.3 1.7	270 46 22 42 23

#	Article	IF	Citations
19	The bone marrow microenvironment in health and disease at a glance. Journal of Cell Science, 2018, 131, .	1.2	51
20	Et tu, E2F1? The assassins of CML stem cells. Blood, 2018, 131, 1499-1500.	0.6	1
21	Targeting the bone marrow microenvironment in acute leukemia. Leukemia and Lymphoma, 2018, 59, 2535-2545.	0.6	25
22	Specific and Targetable Interactions with the Bone Marrow Microenvironment Govern Outcome in Imatinib-Resistant Chronic Myeloid Leukemia. Blood, 2018, 132, 936-936.	0.6	1
23	The Vascular Bone Marrow Niche Influences Outcome in Chronic Myeloid Leukemia. Blood, 2018, 132, 3846-3846.	0.6	2
24	Histological and In Vivo Microscopic Analysis of the Bone Marrow Microenvironment in a Murine Model of Chronic Myelogenous Leukemia. Methods in Molecular Biology, 2016, 1465, 59-72.	0.4	0
25	Single-Stranded DNA-Binding Transcriptional Regulator FUBP1 Is Essential for Fetal and Adult Hematopoietic Stem Cell Self-Renewal. Cell Reports, 2015, 11, 1847-1855.	2.9	30
26	The inward rectifier potassium channel Kir2.1 is expressed in mouse neutrophils from bone marrow and liver. American Journal of Physiology - Cell Physiology, 2015, 308, C264-C276.	2.1	36
27	A hostel for the hostile: the bone marrow niche in hematologic neoplasms. Haematologica, 2015, 100, 1376-1387.	1.7	90
28	The Corepressor Tle4 Is a Novel Regulator of Murine Hematopoiesis and Bone Development. PLoS ONE, 2014, 9, e105557.	1.1	27
29	Selectins and their ligands are required for homing and engraftment of BCR-ABL1+ leukemic stem cells in the bone marrow niche. Blood, 2014, 123, 1361-1371.	0.6	88
30	Flow Cytometry for Hematopoietic Cells. Methods in Molecular Biology, 2014, 1109, 23-46.	0.4	7
31	Focal Adhesion Kinase Inhibitors Reverse the Stromal Adhesion Phenotype of Ikaros-Mutant B-ALL, Induce Apopotosis, and Synergize with ABL1 Tyrosine Kinase Inhibitors: A New Paradigm for Pathogenesis and Therapy of High-Risk B-ALL. Blood, 2014, 124, 285-285.	0.6	3
32	The Microanatomy of the Leukemic Stem Cell Niche in Murine Chronic Myelogenous Leukemia. Blood, 2014, 124, 351-351.	0.6	2
33	Differential regulation of myeloid leukemias by the bone marrow microenvironment. Nature Medicine, 2013, 19, 1513-1517.	15.2	233
34	Myelopoiesis is regulated by osteocytes through Gsl±-dependent signaling. Blood, 2013, 121, 930-939.	0.6	146
35	The hematopoietic stem cell niche—home for friend and foe?. Cytometry Part B - Clinical Cytometry, 2013, 84B, 7-20.	0.7	75
36	Retargeting NK-92 cells by means of CD19- and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity. Oncolmmunology, 2013, 2, e26527.	2.1	154

3

#	Article	IF	CITATIONS
37	The Transcriptional corepressorTle4 Is a Novel Regulator Of Murine Hematopoietic Stem and Progenitor Cells and Their Niche. Blood, 2013, 122, 588-588.	0.6	1
38	BCR-ABL1+ Leukemic Stem Cells Are Dependent On Selectin-Ligand Interactions For Engraftment In The Bone Marrow Niche. Blood, 2013, 122, 2703-2703.	0.6	0
39	Deconstructing the Complexity of a Microenvironmental Niche. Cell, 2012, 149, 16-17.	13.5	13
40	Differential Regulation of Myeloid Leukemias by the Bone Marrow Microenvironment. Blood, 2012, 120, 1245-1245.	0.6	1
41	Tle4 Is Critical for Proper B- Cell Differentiation and Maintenance of the Murine Bone Marrow Niche. Blood, 2012, 120, 1202-1202.	0.6	3
42	Parathyroid Hormone-Induced Modulation of the Bone Marrow Microenvironment Reduces Leukemic Stem Cells in Murine Chronic Myelogenous-Leukemia-Like Disease Via a TGFbeta-Dependent Pathway. Blood, 2011, 118, 1670-1670.	0.6	1
43	Osteocytes Support Hematopoiesis by Altering the Bone Marrow Microenvironment Through Gsl± Signaling. Blood, 2011, 118, 219-219.	0.6	4
44	The Concentration of CD44 Is Increased in Hematopoietic Stem Cell Grafts of Patients With Acute Myeloid Leukemia, Plasma Cell Myeloma, and Non-Hodgkin Lymphoma. Archives of Pathology and Laboratory Medicine, 2010, 134, 1033-1038.	1.2	15
45	Parathyroid Hormone-Induced Modulation of the Bone Marrow Microenvironment Inhibits the Development of Murine Chronic Myelogenous-Leukemia-Like Disease. Blood, 2010, 116, 937-937.	0.6	0
46	Immune Reconstitution and Clinical Outcome After Donor Lymphocyte Infusion for Relapsed Disease After Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation in Diseases Other Than Chronic Myelogenous Leukemia Blood, 2009, 114, 3316-3316.	0.6	2
47	Right on target: eradicating leukemic stem cells. Trends in Molecular Medicine, 2007, 13, 470-481.	3.5	126
48	Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nature Reviews Cancer, 2007, 7, 332-344.	12.8	720
49	Soluble CD44 Is Increased in Haematopoietic Stem Cell Grafts of Patients with Acute Myeloid Leukemia, Multiple Myeloma and Non-Hodgkin's Lymphoma Blood, 2007, 110, 3286-3286.	0.6	0
50	Requirement for CD44 in homing and engraftment of BCR-ABL–expressing leukemic stem cells. Nature Medicine, 2006, 12, 1175-1180.	15.2	388
51	CD44 Is Selectively Required for the Homing and Engraftment of BCR-ABL-Expressing Leukemic Stem Cells Blood, 2006, 108, 743-743.	0.6	0
52	Tyrosine Kinases as Targets for Cancer Therapy. New England Journal of Medicine, 2005, 353, 172-187.	13.9	1,255
53	Molecular Pathogenesis of Polycythemia Induced in Mice by JAK2 V617F Blood, 2005, 106, 116-116.	0.6	4
54	Selectins and Their Ligands Are Required for Homing and Engraftment of BCR-ABL+ Leukemia-Initiating Cells Blood, 2005, 106, 697-697.	0.6	4